3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Ben Jawdat of Revterra, Pete O'Heeron of FibroBiologics, and Jay Manouchehri of Fluence Analytics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Ben Jawdat, CEO and founder of Revterra

Ben Jawdat, CEO and founder of Revterra, joins the Houston Innovators Podcast. Photo via LinkedIn

Ben Jawdat founded Revterra in Houston based on a unique kinetic energy storage technology. The company has created away to better optimize existing grid-based electric vehicle charging ports while still minimizing a carbon footprint. The startup hopes to be a major player within the energy transition.

"We really want to be an enabling technology in the renewable energy transition," Jawdat says. "One part of that is facilitating the development of large-scale, high-power, fast-charging networks. But, beyond that, we see this technology as a potential solution in other areas related to the clean energy transition."

He shares more about what's next for Revterra on the podcast. Read more and listen to the episode.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release. Read more.

Jay Manouchehri, CEO of Fluence Analytics

Fluence Analytics has exited to a multinational Japanese engineering and software giant. Image via FluenceAnalytics.com

Yokogawa, which has its US operations based in Sugar Land, acquired Fluence Analytics Inc. in a deal announced last week. The terms of the deal were not disclosed and, effective immediately, the company operate as Yokogawa Fluence Analytics. Jay Manouchehri, who joined the company in 2022, will continue to serve as CEO of the entity.

“Combining forces with Yokogawa Electric enables us to capture the full value of our unique data sets, and we can't wait to deliver this added value to our customers," Manouchehri says in a news release. "Together, we will enable autonomous operations and digital transformation in the polymer and biopharma industries."

Founded in 2012 in New Orleans, Fluence Analytics moved to Houston in 2021 following a $7.5 million venture capital raise led by Yokogawa Electric Corp., which has its North American headquarters in Sugar Land. Read more.

From Your Site Articles
You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


This week's roundup of Houston innovators includes Allie Danziger of Ampersand Professionals, Pete O'Heeron of Fibrobiologics, and Brandy Guidry of The Cannon. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health innovation to job training technology — recently making headlines in Houston innovation.

Allie Danziger, founder and CEO of Ampersand Professionals

After working with thousands of interns, Allie Danziger of Ampersand Professionals says she's now got a product to upskill and train new hires for employers. Photo courtesy of Ampersand

Allie Danziger is taking the workforce development programming she's created for training and matching interns with businesses to a whole new level. The new offering gives companies an opportunity to streamline their onboarding process with Ampersand's plug-and-play programming.

Danziger says usually new hires need the most experienced mentor or manager, but they don't usually get that support — especially when it comes to businesses that don't have their own built-out mentorship or training program.

"Ampersand’s new training product fills that gap — it gives employers of any size any easy solution to provide basic job readiness training to employees, access to our team of dedicated coaches, and a detailed report at the end of their training summarizing how their new hire did in the training and any trends recognized and tips for managing this employee based on what the platform uncovered," she says. "Businesses can also sign up for additional coaching sessions and customize training materials, as an add-on if interested." Click here to read more.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Fibroblasts have so much potential for a wide range of cell therapy treatments — the opportunities are endless, according to Pete O’Heeron, CEO, founder, and chairman of FiberBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FiberBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says on last week's episode of the Houston Innovators Podcast. "There's literally not biological process in the body where fibroblasts are not involved." Click here to listen to the episode and read more.

​Brandy Guidry, Pearland navigator at The Cannon

The Pearland Innovation Hub celebrates its launch this month. Photo via pearlandinnovationhub.com

The Pearland Economic Development Corp. has launched the Pearland Innovation Hub, aimed at connecting small businesses with programs and services that are designed to contribute to their success.

The Pearland Innovation Hub is managed through a partnership between the Pearland Economic Development Corp. and The Cannon, a Houston-area business networking community for entrepreneurs, investors, and corporate innovators. For now, the hub does not officially have a physical space. The Cannon hired Brandy Guidry to run the Pearland hub. She has more than 17 years of experience in business operations; engineering; technical marketing; innovation; and strategic planning, project, and program management.

“The Pearland Innovation Hub is a groundbreaking initiative to support existing and aspiring small business owners,” Guidry adds. Click here to read more.


Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Houston cell therapy company prepares to IPO, move into new facility

Houston Innovators Podcast episode 135

Stem cells have had their time in the spotlight for a while, and now it's time for fibroblasts to have their moment, according to Pete O’Heeron, CEO, founder, and chairman of FibroBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

The two types of cells are the only ones that can be used in cell therapy for a regenerative treatment, meaning that specialists can take healthy stem cells and fibroblasts from a patient and inject them into a part of the body that needs it the most. And, according to O'Heeron and his team, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron on this week's Houston Innovators Podcast. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FibroBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says. "There's literally not biological process in the body where fibroblasts are not involved."

The strongest treatments under FibroBiologics's umbrella are for degenerative disc disease, orthopedics, multiple sclerosis, and cancer. With these applications progressing, O'Heeron has imminent IPO plans for the company.

"We're in the process of getting the company public so that we can have access to the resources to do larger scale human trials. So, I think over the next year you'll see us launch at least two large scale human trials with fibroblast with the intention of submitting to the FDA for commercialization," O'Heeron says.

The company is in the process of building out a new 14,000-square-foot-space that will allow FibroBiologics to house its office, lab, and manufacturing space under one roof for the first time.

"These are fantastic robust cells, and we want to be able to control the quality and potency of them and how they ship out and how we're able to transfer those cells to the end user," O'Heeron says.

He shares more about the company and the impact he expects fibroblasts to have on cell therapy treatment. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


This innovative health care company has announced some big moves. Photo via Fibrobiologics.com

Houston health care company raises $100M and plans to IPO

big moves

A clinical stage therapeutic company has made some big moves — with an even bigger one on the horizon.

FibroBiologics, which is developing fibroblast-based therapeutic cures for chronic diseases, announced $100 million in fresh funding resulting from an agreement with GEM Global Yield LLC SCS, a private investment group, with offices in New York and Paris. The funds will be distributed over a 36-month term following a public listing of FibroBiologics common stock.

According to a news release, "FibroBiologics will control the timing and maximum amount of the drawdown under this facility and has no minimum drawdown obligation." The IPO could include acquisition via SPAC.

"This Agreement with GEM helps secure additional funding to further develop cell therapy cures in Multiple Sclerosis, Degenerative Disc Disease and Cancer using fibroblast cells," says Pete O'Heeron, CEO and chairman of FibroBiologics, in the release. "This Agreement provides for a strong balance sheet upon public listing and positions FibroBiologics for the next stage of commercial development to deliver life-changing abatement for patients with incurable chronic diseases."

Founded earlier this year, FibroBiologics offices in Southeast Houston adjacent to the University of Houston-Clear Lake campus, where O'Heeron completed his Masters in Healthcare Administration.

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

NASA awards Texas Space Commission role in $10M aerospace workforce initiative

space hub

The Texas Space Commission is one of seven organizations tapped by NASA to lead the space agency's new state and regional Skilled Technical Workforce Hubs.

The $10.5 million initiative aims to help foster the next generation of skilled workers in the aerospace industry.

Through the new program, the hubs will work together over the next three years to meet growing industry needs by aligning “industry employers, community colleges, high school career and technical education programs, and workforce systems,” according to a news release from NASA.

It aims to create clear pathways for workers in technical jobs, like welding, electrical work and machining, plus other jobs that require advanced STEM knowledge but do not require a bachelor’s degree.

“The need for technical talent is already urgent and will only continue to grow as we return humanity to the Moon and set our sights on Mars and beyond,” Elaine Ho, associate administrator for the Office of STEM Engagement at NASA, said in the release. “NASA is uniquely positioned to be the catalyst and convener that accelerates America’s aerospace workforce development and fosters the next generation of technicians.”

As part of the initiative, the TSC plans to launch the statewide network known as the Texas Space STEM Alliance (TSSA). According to a TSC release, the TSSA will link up schools, colleges, workforce groups and aerospace companies to build a pipeline for space-industry workers.

Additionally, the TSC is developing the Texas Aerospace Pathways Plus (TAP+) portal to consolidate information on training programs, internships, apprenticeships, employment opportunities and scholarships, while also identifying regional gaps in workforce opportunities.

Other state and regional organizations to receive the award include:

  • Antelope Valley Community College District in Lancaster, California
  • Georgia Tech Research Corporation
  • Minnesota State Colleges and Universities
  • Southern Utah University
  • Space Florida
  • State Board for Community Colleges and Occupation Education, Arapahoe Community College in Littleton, Colorado

The Houston area is home to more than 43,000 aerospace and aviation professionals, according to the Greater Houston Partnership. The Texas Space Commission has been awarded $150 million for 24 projects since being established to increase the state’s space economy in 2023.

The funding for the NASA state hubs comes from NASA’s Office of STEM Engagement through its Next Gen STEM Project.

Amazon's robotaxi service Zoox rolls out in 'sprawling' Houston market

On the Road

Amazon-owned robotaxi ride-hailing service Zoox is zooming into Houston in September, becoming the latest robotaxi operator jockeying for local riders.

Initially, self-driving retrofitted SUVs with safety drivers on board will serve downtown Houston, centrally located tourist hotspots, and certain residential neighborhoods. The SUVs will test Houston roads before Zoox rolls out autonomous robotaxis here, the company says.

Zoox takes Houston for a test drive

At the outset, Zoox says, a limited number of vehicles will be driven by people to gather data about Houston roads.

Zoox test drive Photo courtesy of Zoox

“This helps create a detailed picture of each street, from road geometry to traffic lights,” the company says. “Once we have mapped out an area, we will test autonomous driving capabilities. Safety and operational readiness govern the pace of our rollout.”

Zoox says its robotaxi differs from vehicles operated by other ride-hailing services.

The all-electric robotaxi “is purpose-built for autonomous ride-hailing and designed for riders from day one,” the company says. “It has no traditional driving controls and instead has carriage-style seating, sliding glass doors, and features that let the rider personalize their journey.”

To help manage the fleet, Zoox plans to open a depot in Houston for vehicle charging and maintenance, a representative says via email.

Along with Houston, Zoox is launching this month in San Diego. The ride-hailing service already operates in Austin, Dallas, Atlanta, Las Vegas, Los Angeles, Miami, Phoenix, the San Francisco Bay Area, Seattle, and Washington, D.C.

Zoox breaks into “sprawling” Houston market

Zoox describes Houston as its “most sprawling market to date.”

“Driving here means navigating complex service-road networks, unique merging scenarios, and challenging environmental conditions, including severe heat, heavy rain, and urban flooding,” the company says. “It’s a rigorous test of our technology across geography and terrain.”

Zoox will join two other autonomous ride-hailing services in Houston:

  • Waymo began rolling in Houston in February. Alphabet, the parent company of Google, owns Waymo.
  • Electric vehicle manufacturer Tesla began offering robotaxi services earlier this year.

A third Zoox competitor is arriving within the next year. A partnership comprising rideshare provider Uber, EV manufacturer Lucid, and autonomous technology company Nuro plans to launch a robotaxi service in Houston by mid-2027.

---

This article originally appeared on CultureMap.com.

Houston energy giant Shell lists local headquarters for sale for $325M

On the Market

Energy giant Shell has put its U.S. headquarters in Houston’s Energy Corridor on the market and is exploring the sale of its U.S. chemical business.

Green Street News reported Shell just listed its longtime Energy Corridor campus at 150 N. Dairy Ashford Road. The asking price is $325 million, The Real Deal reported. Shell plans to lease back half of the nearly 1.5 million-square-foot Woodcreek campus for 15 years.

A sale-leaseback deal could transform the 43.6-acre campus into a multitenant hub, CoStar News reported.

“Houston is a critical hub for Shell globally and the headquarters of our U.S. businesses,” a Shell spokesperson told the Houston Business Journal. “We remain committed to Houston and are evaluating opportunities to optimize our Woodcreek campus as part of our ongoing review of workplace needs while maintaining a strong presence in the city.”

Shell occupied its first building at the West Houston campus in 1980. The company employs more than 6,000 people in Texas.

Shell is one of the highest-profile businesses occupying space in the Energy Corridor. It’s home to 67,000 workers, more than 27 million square feet of office and mixed-use space, and 3.8 million square feet of retail and restaurant space.

Shell considers $8B sale of chemical business
As the company seeks to unload its Woodcreek campus, The Financial Times reported Shell is looking into selling its U.S. chemical business. The price tag: $8 billion.

Potential buyers include Spring-based ExxonMobil and Houston-based LyondellBasell.

Shell operates four chemical plants in Texas, Louisiana and Pennsylvania, producing an array of chemicals for use in plastics, detergents and pharmaceuticals.

Shell CEO Wael Sawan said last year that the company had spent $45 billion in capital “that is underperforming for us,” split between its chemical business and renewable energy arm.

Shell also agreed to sell its solar and wind power business in India this summer. Read more here.

---

This article originally appeared on EnergyCapitalHTX.com.

View All Listings